Erdafitinib requires structured monitoring because its FGFR inhibition affects both tumor signaling and normal biological pathways.
Ocular toxicity
Ocular toxicity is one of the most clinically distinctive safety concerns.
Erdafitinib can cause retinal pigment epithelial detachment and other retinal disorders. Patients require appropriate eye assessments, and new visual symptoms should be reported promptly.
Hyperphosphatemia
Increased phosphate is a pharmacodynamic effect of FGFR inhibition. Serum phosphate should be monitored, particularly during the early treatment period when the decision about increasing from 8 mg to 9 mg is made.
Stomatitis
Inflammation of the mouth can occur. Oral symptoms should be assessed if persistent or severe because they may interfere with nutrition and quality of life.
Nail toxicity
Erdafitinib may produce nail disorders, including nail dystrophy and onycholysis. Patients should report significant pain, infection-like symptoms or extensive nail changes.
Skin and hand-foot toxicity
Palmar-plantar erythrodysesthesia can cause redness, swelling, tenderness or discomfort affecting the hands and feet.
Gastrointestinal effects
Diarrhea, dry mouth and other gastrointestinal or oral effects may occur. Significant or persistent diarrhea can contribute to dehydration and requires clinical attention.
Drug interactions
Erdafitinib is metabolized primarily by CYP2C9 and CYP3A4. Strong inhibitors or inducers of these pathways can affect exposure. The original FDA pharmacology assessment found increased erdafitinib exposure with fluconazole and itraconazole and predicted clinically important exposure reduction with strong CYP3A4/2C9 induction such as rifampicin.
A complete medication review should therefore be performed before and during treatment.
Pregnancy
Erdafitinib may cause fetal harm based on its mechanism and nonclinical findings. Pregnancy and reproductive potential should be discussed with the treating healthcare professional before treatment.
Breastfeeding
The applicable prescribing information should be consulted regarding breastfeeding. Patients should discuss whether breastfeeding is appropriate with their healthcare professional.
Monitoring
Monitoring may include:
- Serum phosphate
- Eye examinations
- Visual symptoms
- Renal function
- Liver-related laboratory tests
- Oral and gastrointestinal toxicity
- Skin and nail toxicity
- Other clinically indicated assessments